1. Non–small cell lung cancer: general principles, management of localized disease, and treatment of metastatic disease without oncogene drivers;Altan,2022
2. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019
3. KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC;Garassino;Ann Oncol,2022
4. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial;Paz-Ares;J Thorac Oncol,2022
5. 5-year update from KEYNOTE-407: pembrolizumab plus chemotherapy in squamous non–small cell lung cancer;Novello;ESMO Congress,2022